Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed AIDS-related B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:~  * Grade III follicular large cell lymphoma~ * Diffuse large B-cell lymphoma~ * Immunoblastic lymphoma~ * Plasmablastic lymphoma~ * Primary effusion lymphoma~* Previously untreated disease~* Any stage disease~* CD20 positive disease~* Must have documented HIV infection~  * Documentation may be by serology (enzyme-linked immunosorbent assay, western blot), culture, or quantitative polymerase chain reaction or branched DNA assays~ * Prior documentation of HIV seropositivity allowed~* Measurable or nonmeasurable disease~* Currently receiving effective highly active anti-retroviral therapy~* No primary CNS lymphoma, including parenchymal brain or spinal cord lymphoma~* No presence of leptomeningeal disease (positive cerebrospinal fluid for lymphoma) or presence of metastatic disease to brain, in terms of any mass lesion~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%~* Life expectancy ≥ 2 months~* Absolute granulocyte (neutrophil) count ≥ 1,000/mm³ (unless secondary to lymphomatous involvement of bone marrow)~* Platelet count ≥ 75,000/mm³ (unless secondary to lymphomatous involvement of bone marrow or due to HIV-related thrombocytopenia)~* Bilirubin ≤ 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system or due to other HIV medications \[e.g., indinavir, tenofavir, or atazanavir\])~* SGOT ≤ 5 times upper limit of normal~* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min (unless secondary to renal involvement by lymphoma)~* LVEF normal by MUGA or echocardiogram~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after completion of study treatment~* No other malignancy, except nonmelanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma that does not require systemic therapy~* No serious, ongoing, nonmalignant disease or infection that would preclude study compliance, in the opinion of the investigator~* No history of cutaneous or mucocutaneous reactions, or diseases in the past, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for ≥ 2 days~* No acute, intercurrent infection that would preclude study treatment~  * Patients with Mycobacterium avium are eligible~* No cardiovascular problems, including any of the following:~  * Myocardial infarction within the past 6 months~ * New York Heart Association class II-IV heart failure~ * Uncontrolled angina~ * Severe uncontrolled ventricular arrhythmias~ * Clinically significant pericardial disease~ * ECG evidence of acute ischemic or active conduction system abnormalities.~* No shortness of breath at rest~* Arterial PO_2 ≥ 70 or pulse oximeter-derived O_2 saturation ≥ 94% on room air (unless due to lymphomatous involvement of the lungs)~* Able to comply with study and provide adequate informed consent~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 4 weeks since prior major surgery (except diagnostic surgery)~* At least 12 months since prior rituximab unless it was only given for indications other than the treatment of aggressive lymphoma~* No prior cytotoxic chemotherapy or radiotherapy for this lymphoma~  * Concurrent radiotherapy, with or without steroids, for emergency conditions secondary to lymphoma (i.e., CNS tumor or cord compression) allowed~* No zidovudine or zidovudine-containing regimen (including Combivir® or Trizivir®) during and for 2 months after completion of chemotherapy~* Concurrent erythropoietin or filgrastim (G-CSF) allowed~  * Growth factor therapy must be discontinued ≥ 24 hours prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- DR-COP (Type: EXPERIMENTAL): Single arm interventional study: all subjects receive DR-COP regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).